Update shared on19 Sep 2025
Fair value Increased 2.40%RadNet’s consensus price target has risen to $79.29 as analysts cite robust imaging center demand, expanding service opportunities, strong digital health investments, and confidence in management’s strategic execution.
Analyst Commentary
- Robust core imaging center demand trends indicate sustained growth potential.
- Diverse range of new opportunities identified across service lines.
- Continued strong investment in Digital Health initiatives positions the company for future expansion.
- The company is well positioned to leverage growth through opportunistic M&A activities.
- Upbeat management commentary underscores confidence in ongoing strategic initiatives.
What's in the News
- RadNet raised full-year 2025 guidance for Imaging center segment net revenue to $1,850 – $1,900 million.
- RadNet’s AI-powered breast cancer detection program (EBCD) will be reimbursed and provided as a health plan benefit by major medical groups affiliated with Heritage Provider Network; company will proactively increase patient screening compliance.
- RadNet was added to several Russell Value benchmark and index series, including the Russell 2000, 2500, 3000, 3000E, and Small Cap Comp Value indices.
Valuation Changes
Summary of Valuation Changes for RadNet
- The Consensus Analyst Price Target has risen slightly from $77.43 to $79.29.
- The Future P/E for RadNet has significantly risen from 40.79x to 45.01x.
- The Consensus Revenue Growth forecasts for RadNet has fallen from 7.6% per annum to 6.9% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.